Urothelial Cancers

• ESMO E-Learning: Metastatic Urothelial Carcinoma Systemic Second-Line Therapy: The Platinum-Refractory Setting
• Bladder cancer: New treatments and new biomarkers
• ESMO Preceptorship on Advanced Non Resectable Hepatocellular Carcinoma, Biliary and Pancreatic Cancer Paris December 2019
• Development of a biomarker-based calculator to predict the probability to achieve a pathologic complete response after neoadjuvant pembrolizumab in...
• Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung...
• ESMO Preceptorship on Metastatic Bladder and Kidney Cancer Lugano November 2019
• Participants Clinical Case Discussion: Important Clinical Benefit from CT in Metastatic Transitional Cells Bladder Cancer
• Participants Clinical Case Discussion: ICPI in the Context of Autoimmune Diseases
• Immunotherapy
• TKIs and mTOR Inhibitors
• Chemotherapy
• Systemic Chemotherapy is the Standard for Metastatic Urothelial Cancer: NO
• Systemic Chemotherapy is the Standard for Metastatic Urothelial Cancer: YES
• Clinical Application
• Bladder Cancer
• Participants Clinical Case Discussion: Bladder Cancer, III Stage
• Participants Clinical Case Discussion: First-line Ipilimumab-Nivolumab: Sitting in the Turkish Seat of a Patient with Metastatic Renal Cell Cancer
• Metastatic Bladder Cancer: Immunotherapy
• >Metastatic Bladder Cancer: Chemotherapy
• Participants Clinical Case Discussion: Living with Metastatic Kidney Cancer
• Participants Clinical Case Discussion: A Rare Case of Kidney Cancer in Children: Renal Cell Carcinoma
• The Role of Surgery in Metastatic Bladder Cancer
• The Search for Biomarkers in Bladder Cancer
• Welcome from ESMO. Objectives and Scientific Introduction
• Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated...

• « Previous
• 1
• 2
• ...
• 16
• Next »